The NIAID contract awarded in 2018 supports early research and development projects, including GMP manufacturing of Phase I/II clinical material for inclusion in Investigational New Drug (IND) applications and/or Biologic License Applications (BLA).
The purpose of this Task Order is to support a pentavalent vaccine by manufacturing 5 Master Cell Banks. All manufacturing activities will be conducted in the IDT Biologika Rockville, MD, facility.
“It is a great honor to be awarded with this Task Order and we are looking forward to meet the required milestones,” said Jürgen Betzing, chief executive officer, IDT Biologika. “IDT has a long-standing history and proven track record of developing and manufacturing bacterial and virus-based vaccines. Our state-of-the-art manufacturing facility located in Rockville is well positioned to serve the current Task Order requirement.”